MPS Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from MPS Pharma Ltd. on BSE

Load latest

MPS Pharma Ltd.

12 Apr 2024

3.01

4.51%

Company Update

ADVIK LABORATORIES LTD. - 531686 - Confirmation On Non Applicability Of The Criteria Specified Under SEBI …

BSE India

Submission of the declaration that our Company " MPS Pharmaa Limited (formerly known as Advik Laboratories Limited) " does not fall under the category of Large Corporate (LC) as on 31st march, 2024 .

pdf

MPS Pharma Ltd.

11 Apr 2024

3.01

4.51%

Company Update

ADVIK LABORATORIES LTD. - 531686 - Submission Of Compliance Certificate Pursuant To Regulation 7 (3) Of …

BSE India

Attached herewith is the certificate under Reg. 7(3) of SEBI LODR , Regulation, 2015 for the year ended 31.03.2024

pdf

MPS Pharma Ltd.

11 Apr 2024

3.01

4.51%

Company Update

ADVIK LABORATORIES LTD. - 531686 - Statement Of Investor Complaints For The Quarter Ended 31Stmarch, 2024

BSE India

Submission of investor complaint for the quarter ended 31st March, 2024

pdf

MPS Pharma Ltd.

08 Apr 2024

3.01

4.51%

Company Update

ADVIK LABORATORIES LTD. - 531686 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Submission of compliance certificate under Reg. 74(5) of SEBI (DP) Regulation , 2018 for the quarter ended 31st March, 2024

pdf

MPS Pharma Ltd.

30 Mar 2024

3.01

4.51%

SAST

ADVIK LABORATORIES LTD. - 531686 - Closure of Trading Window

BSE India

pfa

pdf

MPS Pharma Ltd.

26 Mar 2024

3.01

4.51%

Board Meeting

ADVIK LABORATORIES LTD. - 531686 - Board Meeting Outcome for Outcome Of Independent Directors Meeting

BSE India

Outcome of Independent Directors Meeting

pdf

MPS Pharma Ltd.

14 Mar 2024, 05:56PM

3.01

4.51%

Board Meeting

ADVIK LABORATORIES LTD. - 531686 - Board Meeting Intimation for Notice Of Separate Meeting Of Independent …

BSE India

ADVIK LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2024 ,inter alia, to consider and approve Dear Sir, Pursuant to Regulation 25(3) of the Securities and Exchange Board of India (LODR) Regulations, 2015 and Schedule IV of the Companies Act, 2013, notice is hereby given that a separate meeting of Independent Directors of the company is scheduled to be held on Tuesday, 26 th March, 2024 at 03:00 P.M. at the corporate office of the company. at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi-110001 to inter-alia, transact the following business: I. To review the performance of non-Independent Directors and the Board as a whole; II. To assess the quality, quantity and timeliness of flow of information between the company management and the Board that is necessary for the Board to effectively and reasonably perform their duties;

pdf

MPS Pharma Ltd.

14 Feb 2024, 04:07PM

3.01

4.51%

Company Update

ADVIK LABORATORIES LTD. - 531686 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Submission of newspaper publication w.r,t un-audited financial results for the quarter ended 31.12.2023

pdf

MPS Pharma Ltd.

13 Feb 2024, 05:47PM

3.01

4.51%

Result

ADVIK LABORATORIES LTD. - 531686 - Un-Audited Financial Results For The Quarter And Nine Months Ended …

BSE India

pfa

pdf

MPS Pharma Ltd.

13 Feb 2024, 05:43PM

3.01

4.51%

Board Meeting

ADVIK LABORATORIES LTD. - 531686 - Board Meeting Outcome for Outcome Of The Board Meeting And …

BSE India

This is to inform you that pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Tuesday, 13 th February, 2024 at 04:30 P.M at the corporate office of the company situated at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001 and concluded just now has, inter-alia, transacted the following business: 1. Considered and approved the Standalone Un-Audited Financial Results of the Companyfor the quarter and nine months ended 31 st December, 2023. 2. Considered and approved the Limited Review Report for the Un-Audited Financial Results of the Company for the quarter and nine months ended 31 st December, 2023. Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Un-Audited Financial Results for the quarter and nine months ended 31st December, 2023along with Limited Review Report are enclosed herewith

pdf

Is Advik Laboratories Ltd. worth buying?

5 Votes:

Buy 40.0%

Sell 20.0%

Hold 40.0%

New 52W Low today

High volume today

MPS Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from MPS Pharma Ltd. on BSE